SENATE, No. 2284

STATE OF NEW JERSEY

212th LEGISLATURE

 

INTRODUCED OCTOBER 23, 2006

 


 

Sponsored by:

Senator ELLEN KARCHER

District 12 (Mercer and Monmouth)

Senator LORETTA WEINBERG

District 37 (Bergen)

 

Co-Sponsored by:

Senator Buono

 

 

 

 

SYNOPSIS

     Requires insurers and State health care coverage programs to cover cost of HPV vaccine.

 

CURRENT VERSION OF TEXT

     As introduced.

  


An Act concerning insurance coverage for HPV vaccine and supplementing Titles 17, 26, 30, and 52 of the Revised Statutes and Title 17B of the New Jersey Statutes.

 

     Be It Enacted by the Senate and General Assembly of the State of New Jersey:

 

     1.  A hospital service corporation contract that provides hospital and medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to P.L.1938, c.366 (C.17:48-1 et seq.), on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the contract.

     This section shall apply to those hospital service corporation contracts in which the hospital service corporation has reserved the right to change the premium.

 

     2.  A medical service corporation contract that provides hospital and medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to P.L.1940, c.74 (C.17:48A-1 et seq.), on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the contract.

     This section shall apply to those medical service corporation contracts in which the medical service corporation has reserved the right to change the premium.

 

     3.  A health service corporation contract that provides hospital and medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to P.L.1985, c.236 (C.17:48E-1 et seq.), on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the contract.

     This section shall apply to those health service corporation contracts in which the health service corporation has reserved the right to change the premium.

 

     4.  An individual health insurance policy that provides hospital and medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to chapter 26 of Title 17B of the New Jersey Statutes, on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the policy.

     This section shall apply to those policies in which the insurer has reserved the right to change the premium.

 

     5.  A group health insurance policy that provides hospital and medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to chapter 27 of Title 17B of the New Jersey Statutes, on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the policy.

     This section shall apply to those policies in which the insurer has reserved the right to change the premium.

 

     6.  An individual health benefits plan that is delivered, issued, executed or renewed in this State pursuant to P.L.1992, c.161 (C.17B:27A-2 et seq.), on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the health benefits plan.

     This section shall apply to those health benefits plans in which the carrier has reserved the right to change the premium.

 

     7.  A small employer health benefits plan that is delivered, issued, executed or renewed in this State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.), on or after the effective date of this act, shall provide benefits for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the health benefits plan.

     This section shall apply to those health benefits plans in which the carrier has reserved the right to change the premium.

 

     8.  A health maintenance organization contract for health care services that is delivered, issued, executed or renewed in this State pursuant to P.L.1973, c.337 (C.26:2J-1 et seq.), on or after the effective date of this act, shall provide health care services for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The health care services shall be provided to the same extent as for any other medical condition under the contract.

     This section shall apply to those contracts for health care services under which the right to change the schedule of charges for enrollee coverage is reserved.

 

     9.  The State Health Benefits Commission shall ensure that every contract purchased by the commission, on or after the effective date of this act, that provides hospital or medical expense benefits shall provide coverage for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The benefits shall be provided to the same extent as for any other medical condition under the program.

 

     10.  The Medicaid program established pursuant to P.L.1968, c.413 (C.30:4D-1 et seq.) and the NJ FamilyCare Program established pursuant to P.L.2005, c.156 (C.30:4J-8 et al.) shall provide coverage for expenses incurred for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

 

     11.  This act shall take effect on the 90th day after enactment, and shall apply to policies or contracts issued or renewed on or after the effective date.

 

 

STATEMENT

 

     This bill requires that health insurers (hospital, medical and health service corporations, commercial individual, small employer and larger group insurers, and health maintenance organizations), the State Health Benefits Program, and the State Medicaid and NJ FamilyCare programs provide coverage for a vaccination against the human papillomavirus (HPV) that is approved for marketing by the federal Food and Drug Administration.

     The federal Food and Drug Administration recently approved a vaccine to prevent cervical cancer, precancerous genital lesions and genital warts due to certain types of human papillomavirus (HPV). The vaccine, Gardasil (manufactured by Merck & Co., Inc.), is approved for use in females nine to 26 years of age.

     HPV is the most common sexually-transmitted infection in this country.  The Centers for Disease Control and Prevention estimates that about 6.2 million Americans become infected with genital HPV each year, and that over 50% of all sexually active men and women become infected at some time in their lives.  For most women, the body’s own defense system will clear the virus and infected women will not develop related health problems; however, some types of HPV can cause abnormal cells on the lining of the cervix that may become cancerous.  Other types of HPV can cause genital warts.  The recently approved vaccine is effective against two types of HPV that cause approximately 70% of cervical cancers, and two types of HPV that cause approximately 90% of genital warts.